Caris Life Sciences introduced its Caris Assure liquid biopsy assay on Friday at the 2022 American Society of Clinical Oncology (ASCO) annual meeting in Chicago.
The blood-based molecular profiling assay uses a circulating nucleic acids sequencing approach to analyze the whole exome (cfDNA) and whole transcriptome (cfRNA) of 22,000 genes from a blood sample, including loss of heterozygosity, microsatellite instability, and tumor mutational burden.
The assay also enables minimally invasive serial monitoring for the detection of tumor heterogeneity and emergence of resistance mutations, Caris said.
In an initial performance validation study, the assay demonstrated a sensitivity of more than 95% for variant frequencies greater than 0.5% and a specificity of greater than 99.99%, the firm said.
It added that Caris Assure will be commercially available in the second half of this year, with limited availability in Q3 and expanded availability in Q4, as well as in 2023.